- Home
- GUTS vs OTLK Comparison
GUTS vs OTLK Comparison
Compare GUTS & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- OTLK
- Stock Information
- Founded
- GUTS 2010
- OTLK 2010
- Country
- GUTS United States
- OTLK United States
- Employees
- GUTS N/A
- OTLK N/A
- Industry
- GUTS
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GUTS
- OTLK Health Care
- Exchange
- GUTS NYSE
- OTLK Nasdaq
- Market Cap
- GUTS 58.8M
- OTLK 48.3M
- IPO Year
- GUTS 2024
- OTLK 2016
- Fundamental
- Price
- GUTS $1.60
- OTLK $1.57
- Analyst Decision
- GUTS Buy
- OTLK Strong Buy
- Analyst Count
- GUTS 1
- OTLK 5
- Target Price
- GUTS $10.00
- OTLK $9.60
- AVG Volume (30 Days)
- GUTS 916.8K
- OTLK 845.9K
- Earning Date
- GUTS 08-13-2025
- OTLK 08-13-2025
- Dividend Yield
- GUTS N/A
- OTLK N/A
- EPS Growth
- GUTS N/A
- OTLK N/A
- EPS
- GUTS N/A
- OTLK 0.83
- Revenue
- GUTS $60,000.00
- OTLK N/A
- Revenue This Year
- GUTS N/A
- OTLK N/A
- Revenue Next Year
- GUTS N/A
- OTLK $379.84
- P/E Ratio
- GUTS N/A
- OTLK $1.93
- Revenue Growth
- GUTS N/A
- OTLK N/A
- 52 Week Low
- GUTS $0.87
- OTLK $0.87
- 52 Week High
- GUTS $4.92
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- GUTS 43.49
- OTLK 40.37
- Support Level
- GUTS $1.54
- OTLK $1.65
- Resistance Level
- GUTS $1.82
- OTLK $2.04
- Average True Range (ATR)
- GUTS 0.18
- OTLK 0.12
- MACD
- GUTS -0.07
- OTLK -0.03
- Stochastic Oscillator
- GUTS 10.13
- OTLK 2.13
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.